Abstracts tagged "interstitial lung disease"

Abstract Number: 1837 • ACR Convergence 2021
KL-6, CXCL11 and CTGF Are Potential Biomarkers in Response to Treatment in CTD-ILD
Yu-Hsiang Chiu¹, Mareye Voortman¹, Eveline Delemarre¹, Stefan Nierkens¹, Pim de Jong¹, Firdaus Mohamed Hoesein¹, Jan Grutters², Jacob van Laar¹ and Julia Spierings³, ¹University Medical Centre Utrecht, Utrecht, Netherlands, ²St. Antonius Hospital, Nieuwegein, Netherlands, ³University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Connective tissue disease related interstitial lung disease (CTD-ILD) is common and an important cause of morbidity and mortality. We aimed to identify biomarkers in…
Abstract Number: 0202 • ACR Convergence 2021
Variables Associated with Response to Therapy in Patients with Interstitial Pneumonia with Autoimmune Features
Elena Joerns¹, Traci Adams¹, Chad Newton¹, Lesley Davila², Kiran Batra¹, Jose Torrealba¹, Craig Glazer¹, Joan Reisch¹, Bonnie Bermas³, David Karp² and Una Makris⁴, ¹UT Southwestern, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX, ³UTSouthwestern Medical Center, Dallas, TX, ⁴UT Southwestern Medical Center, Dallas Veterans Administration, Dallas, TX
Background/Purpose: We have limited knowledge of the characteristics of patients with interstitial pneumonia with autoimmune features (IPAF) that are associated with response to immunosuppression. Thus,…
Abstract Number: 0496 • ACR Convergence 2021
Safety and Efficacy of Rituximab for Systemic Sclerosis: A Double-Blind, Parallel-Group Comparison, Investigators Initiated Confirmatory Randomized Clinical Trial (DESIRES Study)
Satoshi Ebata¹, Ayumi Yoshizaki¹, Koji Oba², Kosuke Kashiwabara³, Keiko Ueda³, Yukari Umemura⁴, Takeyuki Watadani⁵, Takemichi Fukasawa¹, Shunsuke Miura¹, Asako Yoshizaki-Ogawa¹, Yoshihide Asano¹, Naoko Okiyama⁶, Masanari Kodera⁷, Minoru Hasegawa⁸ and Shinichi Sato¹, ¹Department of Dermatology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ²Department of Biostatistics, School of Public Health, Graduate School of Medicine, and Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan, ³Clinical Research Support Center, The Tokyo University Hospital, Tokyo, Japan, ⁴Biostatistics Section, Department of Data Science, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan, ⁵Department of Diagnostic Radiology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan., Tokyo, Japan, ⁶Department of Dermatology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan., Ibaraki, Japan, ⁷Department of Dermatology, Japan Community Health Care Organization Chukyo Hospital, Aichi, Japan., Aichi, Japan, ⁸Department of Dermatology, Division of Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan., Fukui, Japan
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease belonging to collagen diseases, characterized by fibrosis of various organs including the skin and lungs, and…
Abstract Number: 1021 • ACR Convergence 2021
Organic Dust Exposure Induces Post-translational Protein Modifications and a HLA-DR4-dependent Pro-inflammatory Lung Phenotype in a Murine Model of Interstitial Lung Disease
Jill Poole¹, Ted Mikuls¹, Amy Nelson¹, Rohit Gaurav¹, Michael Duryee¹, Geoffrey Thiele¹, Bryant England¹ and Dana Ascherman², ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Environmental and occupational exposures have been epidemiologically linked to the development of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Previous investigation and modeling have also…
Abstract Number: 1840 • ACR Convergence 2021
Can Dual-energy CT Lung Perfusion Detect Abnormalities at the Level of Lung Circulation in Systemic Sclerosis (SSc) ? Preliminary Experience in 101 Patients
Vincent Koether¹, Antoine Dupont², Julien Labreuche³, Paul Felloni⁴, Thierry Perez⁵, Pascal Degroote⁵, Jacques Remy⁴, Martine Remy-Jardin⁵ and David Launay⁶, ¹CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de référence des maladies autoimmunes systémiques rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, ²CHRU de Lille, Hopital Calmette, Lille, France, ³CHU Lille, Lille, ⁴CHU Lille; Hopital Calmette, Lille, France, ⁵CHU Lille, Lille, France, ⁶Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France, Lille Cedex, France
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disorder that is characterized by a interplay of vascular abnormalities, immune system activation and an uncontrolled fibrotic response…
Abstract Number: 0281 • ACR Convergence 2021
Unsupervised Machine Learning of Expanded Autoantibodies, Cytokines, and Chemokines Improves the Identification of Interstitial Lung Disease in Rheumatoid Arthritis
Bryant England¹, Dana Ascherman², Michael Duryee¹, Carlos Hunter¹, Yangyuna Yang¹, Punyasha Roul¹, Harlan Sayles¹, Fang Yu¹, Jill Poole¹, Joshua Baker³, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Interstitial lung disease (ILD) frequently complicates the rheumatoid arthritis (RA) disease course, leading to significant morbidity and premature mortality. RA-ILD may be underdiagnosed or…
Abstract Number: 0497 • ACR Convergence 2021
Efficacy in Patient Subgroups in the INCREASE Trial, a Phase III Trial to Evaluate Inhaled Treprostinil in Patients with Pulmonary Hypertension Due to Parenchymal Lung Disease
Victor Tapson¹, Steven Nathan², Reda Girgis³, James Runo⁴, Remzi Bag⁵, Arunabh Talwar⁶, Peter Smith⁷, Lisa Edwards⁷, Christine Park⁷ and Aaron Waxman⁸, ¹Cedars-Sinai, Los Angeles, CA, ²Inova Fairfax, Falls Church, VA, ³Michigan State University, Lansing, MI, ⁴University of Wisconsin, Madison, WI, ⁵University of Chicago, Chicago, IL, ⁶Hofstra Northwell School of Medicine, Hempstead, NY, ⁷United Therapeutics Corporation, Durham, NC, ⁸Brigham and Women's Hospital, Boston, MA
Background/Purpose: INCREASE was a 16-week trial evaluating the safety and efficacy of inhaled treprostinil (iTRE) in patients with pulmonary hypertension associated with interstitial lung disease…
Abstract Number: 1022 • ACR Convergence 2021
Incidence of Antisynthetase Syndrome and Risk of Malignancy in a Population-based Cohort (1998-2019)
Caitrin Coffey¹, Li Wang¹, Stephanie Duong¹, Cassondra Hulshizer¹, Cynthia Crowson², Jay Ryu¹ and Floranne Ernste¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: The antisynthetase syndrome (ASSD) is a distinct subgroup of the idiopathic inflammatory myopathies characterized by myositis, interstitial lung disease, inflammatory arthritis, Raynaud’s phenomenon and…
Abstract Number: 1842 • ACR Convergence 2021
Peripheral Blood Cell Gene Expression Profiling Predicts Response to Mycophenolate in Systemic Sclerosis Related Interstitial Lung Disease
Shervin Assassi¹, Wenjin Zheng², Elizabeth Volkmann³, Xuan Wang⁴, Holly Wilhalme⁵, Marka Lyons⁶, Michael Roth⁵ and Donald Tashkin⁵, ¹University of Texas McGovern Medical School at Houston, Houston, TX, ²School of Biomedical Informatics at the University of Texas Health Science Center at Houston, Houston, TX, ³Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA, ⁴Baylor Scott & White Health, Dallas, TX, ⁵University of California Los Angeles, Los Angeles, CA, ⁶Division of Rheumatology, University of Texas McGovern Medical School at Houston, Houston, TX
Background/Purpose: Response to immunosuppression is variable in systemic sclerosis (SSc) related interstitial lung disease (ILD). Contrary to pulmonary tissue, peripheral blood cell (PBC) RNA can…
Abstract Number: 0289 • ACR Convergence 2021
Developing a Score to Predict Preclinical Interstitial Lung Disease in Patients with Rheumatoid Arthritis – a Cross-Sectional Study from the ESPOIR Cohort
Pierre Antoine Juge¹, Benjamin Granger², Marie-Pierre Debray³, Esther Ebstein⁴, Fabienne Louis-sidney⁵, Joanna Kedra⁶, Raphaël Borie⁷, Arnaud Constantin⁸, Bernard Combe⁹, Rene-Marc FLIPO¹⁰, Xavier Mariette¹¹, Olivier Vittecoq¹², Alain Saraux¹³, Guillermo CARVAJAL-ALEGRIA¹⁴, Jean Sibilia¹⁵, Francis Berenbaum¹⁶, Caroline Kannengiesser¹⁷, Catherine Boileau¹⁷, Bruno Crestani¹⁸, Bruno Fautrel¹⁹ and Philippe Dieudé²⁰, ¹Hopital Bichat-Claude Bernard, Service de Rhumatologie, Paris, France, ²Département de Santé Publique, Hopital de la Pitié Salpétrière, Paris, France, ³Hopital Bichat, Service de Radiologie, Paris, France, ⁴Hopital Bichat, Service de Rhumatologie, Paris, ⁵University Hospital Martinique, Fort de France, Martinique, ⁶Sorbonne Universit, Institut Pierre Louis d'Epidmiologie et de Sant Publique, Paris, France, ⁷Hopital Bichat, Service de Pneumologie, Paris, ⁸Toulouse University Hospital, Toulouse Cedex 9, France, ⁹CHU Montpellier Montpellier University, Montpellier, France, ¹⁰Lille University Hospital, Lille, France, ¹¹Université Paris- Saclay, Rheumatology, Paris, France, ¹²CHU de Rouen, Service de Rhumatologie, Rouen, France, ¹³CHU de Brest, Brest Cedex, France, ¹⁴CHU de Brest, Service de Rhumatologie, Brest, ¹⁵CHU de Strasbourg, Service de Rhumatologie, Strasbourg, France, ¹⁶Sorbonne Universit - hopital Saint-Antoine, Paris, France, ¹⁷CHU de Bichat, Service de Génétique, Paris, France, ¹⁸Hopital Bichat, Paris University, Paris, France, ¹⁹Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ²⁰CHU de Bichat, Service de Rhumatologie, Paris, France
Background/Purpose: Interstitial lung disease (ILD) can be detected in 20% to 60% of patients with rheumatoid arthritis (RA) on high-resolution computed-tomography (HRCT) chest scan and…
Abstract Number: 0529 • ACR Convergence 2021
COPA Syndrome-associated Mutations in Lung Transplant Recipients for Interstitial Lung Disease
Sarah Beshay¹, Isabella Osuna², Jessica Smith¹, Justin Branch³, Laura Muruato³, Marietta DeGuzman³, Pamela McShane¹, Yuelan Ren¹, Rajeev Singh¹, Manuel Silva Carmona³, Sandeep Sahay¹ and Tiphanie Vogel³, ¹Houston Methodist, Houston, ²Rice University, Houston, TX, ³Baylor College of Medicine, Houston, TX
Background/Purpose: COPA syndrome is a rare monogenic cause of immune-mediated lung disease, and it can mimic rheumatic diseases including rheumatoid arthritis (RA) with ILD, lupus…
Abstract Number: 1101 • ACR Convergence 2021
Atypical Pulmonary Radiographic Findings May Help Identify Patients with Usual Interstitial Pneumonia and Autoimmune Features
Fredeswinda Romero Bueno¹, Carmelo Palacios¹, Maria Jesus Rodriguez Nieto¹, Maria Tello Lasheras¹, Angel Rodriguez Leon², Maria Carmen Vegas Sanchez¹, Gabriel Herrero-Beaumont³ and Olga Sanchez Pernaute¹, ¹University Hospital "Fundación Jimenez Diaz", Madrid, Spain, ²Autonoma University of Madrid, Madrid, Spain, ³University Hospital "Fundacion Jimenez Diaz", Madrid, Spain
Background/Purpose: Once specific etiologic factors have been ruled out, the majority of patients with chronic interstitial pneumonia (IP) can be classified as idiopathic pulmonary fibrosis…
Abstract Number: 1844 • ACR Convergence 2021
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated ILD (SSc-ILD) and Differing Comorbidity Burden: Subgroup Analyses of the SENSCIS Trial
Kristin B Highland¹, Teng Moua², Martin Aringer³, Takashi Ogura⁴, Corinna Miede⁵, Margarida Alves⁶ and Virginia Steen⁷, ¹Cleveland Clinic, Cleveland, OH, ²Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, MN, ³Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, ⁴Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Centre, Yokohama, Japan, ⁵mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach, Germany, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁷Division of Rheumatology, Georgetown University, Washington, DC
Background/Purpose: In the SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) vs placebo. Patients with SSc-ILD…
Abstract Number: 0290 • ACR Convergence 2021
Prevalence and Predictors of Mortality in Rheumatoid Arthritis-Related Lung Disease: Results from a Single Center Study
Didem Sahin Eroglu¹, Anil Colaklar², Serdar Baysal³, Murat Torgutalp¹, Asaf Baygul⁴, Serdar Sezer¹, Emine Aydemir Guloksuz¹, Mehmet Yuksel¹, Mucteba Yayla¹, Emine Uslu yurteri⁵, Caglar Uzun², Ozlem Ozdemir kumbasar⁴, Murat Turgay¹, Kinikli Gulay¹ and Askin Ates¹, ¹Ankara University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²Ankara University Faculty of Medicine, Department of Radiology, Ankara, Turkey, ³Ankara University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ⁴Ankara University Faculty of Medicine, Department of Pulmonology, Ankara, Turkey, ⁵Hatay Training and Research Hospital, Hatay, Turkey
Background/Purpose: Rheumatoid arthritis-related lung disease (RA-LD) is a common manifestation of rheumatoid arthritis (RA) and associated with excess mortality. Many studies to date were focused…
Abstract Number: 0561 • ACR Convergence 2021
Enhancing the Identification of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Electronic Health Records Through Text Mining of Computerized Tomography Reports
Brent Luedders¹, Brendan Cope², Matt Devries², W. Scott Campbell², James Campbell², Ted Mikuls³, Jeffrey Curtis⁴, Daniel Hershberger³ and Bryant England³, ¹University of Nebraska Medical Center, Omaha, NE, United Kingdom, ²University of Nebraska Medical Center, Omaha, ³University of Nebraska Medical Center, Omaha, NE, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Interstitial lung disease (ILD) is an extraarticular manifestation of RA that leads to increased morbidity and mortality. Algorithms incorporating multiple diagnostic and procedure codes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].